Deciphera Pharmaceuticals (DCPH) Lifted to “Hold” at BidaskClub

BidaskClub upgraded shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a sell rating to a hold rating in a report issued on Wednesday.

A number of other equities research analysts have also issued reports on the company. Zacks Investment Research upgraded Deciphera Pharmaceuticals from a hold rating to a buy rating and set a $22.00 target price for the company in a research note on Monday, December 25th. Nomura assumed coverage on Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set a buy rating and a $57.00 price objective for the company. Piper Jaffray Companies assumed coverage on Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set an overweight rating and a $35.00 price objective for the company. Instinet assumed coverage on Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set a buy rating and a $57.00 price objective for the company. Finally, JMP Securities assumed coverage on Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set an outperform rating and a $38.00 price objective for the company. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $39.83.

Shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) opened at $25.81 on Wednesday. Deciphera Pharmaceuticals has a 12 month low of $15.15 and a 12 month high of $26.59. The stock has a market capitalization of $868.10 and a PE ratio of -6.52.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its earnings results on Tuesday, November 14th. The company reported ($5.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($5.30). research analysts expect that Deciphera Pharmaceuticals will post -2.91 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new position in Deciphera Pharmaceuticals during the 3rd quarter worth approximately $143,000. FNY Managed Accounts LLC bought a new position in Deciphera Pharmaceuticals during the 3rd quarter worth approximately $153,000. Pura Vida Investments LLC bought a new position in Deciphera Pharmaceuticals during the 3rd quarter worth approximately $1,329,000. Sphera Funds Management LTD. bought a new position in Deciphera Pharmaceuticals during the 3rd quarter worth approximately $1,424,000. Finally, Perceptive Advisors LLC bought a new position in Deciphera Pharmaceuticals during the 3rd quarter worth approximately $1,946,000. 43.94% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Deciphera Pharmaceuticals (DCPH) Lifted to “Hold” at BidaskClub” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.com-unik.info/2018/01/06/deciphera-pharmaceuticals-dcph-lifted-to-hold-at-bidaskclub.html.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

What are top analysts saying about Deciphera Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Deciphera Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit